SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
HCWB reported Three and nine months ended September 30, 2026 results. The price and volatility reaction is pending.
HCWBearnings

Earnings reactions, page 2

HCW Biologics Inc. (HCWB) FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP revenues for the three months ended September 30, 2026, were $55,463, compared to $15,606 for the same period in 2025.
  • GAAP research and development expenses for the three months ended September 30, 2026, were $1,242,577, compared to $1,404,247 for the same period in 2025.
  • GAAP general and administrative expenses for the three months ended September 30, 2026, were $1,366,386, compared to $1,884,994 for the same period in 2025.
  • GAAP net loss for the three months ended September 30, 2026, was $3,222,829, compared to $4,554,336 for the same period in 2025.
  • The Company raised $8.6 million of equity financing in the nine months ended September 30, 2026.
  • The Company secured up to $10.0 million in cash through debt financing on November 4, 2026.

Guidance

  • Phase 1 readout and determination of the Recommended Phase 2 Dose for HCW9302 are expected in the first quarter of 2027.
  • The Company intends to file an IND application to support a first-in-human clinical study to evaluate HCW11-018b in the first half of 2027.

Notes

As of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →